MAPK/ERK pathway
From Proteopedia
(Difference between revisions)
| Line 30: | Line 30: | ||
'''c-Raf''' is part of the MAPK pathway. c-Raf domains include the kinase domain - residues 323-618, cysteine-rich domain – residues 136-187 and Ras-binding domain - residues 51-132. Mutations of c-Raf are possible causes of Noonan syndrome<ref>PMID:23737487</ref>. For details on '''c-Raf''' see [[Molecular Playground/C-Raf]]. | '''c-Raf''' is part of the MAPK pathway. c-Raf domains include the kinase domain - residues 323-618, cysteine-rich domain – residues 136-187 and Ras-binding domain - residues 51-132. Mutations of c-Raf are possible causes of Noonan syndrome<ref>PMID:23737487</ref>. For details on '''c-Raf''' see [[Molecular Playground/C-Raf]]. | ||
| - | ==MAPK== | + | ===MAPK=== |
*[[Mitogen-activated protein kinase]] | *[[Mitogen-activated protein kinase]] | ||
*[[Mitogen-activated protein kinase kinase]] | *[[Mitogen-activated protein kinase kinase]] | ||
Revision as of 12:35, 15 February 2022
| |||||||||||
References
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089
